# 21-Hydroxylase Deficiency

Diagnose suspected 21-hydroxylase deficiency with properly timed 17-hydroxyprogesterone testing, urgently identify salt-wasting risk in newborns, and use cosyntropin steroid profiling and genotyping to resolve equivocal cases while guiding endocrine management and family counseling.

**Clinical question:** How should clinicians confirm 21-hydroxylase deficiency and identify patients at risk for salt-wasting adrenal crisis?

Updated: 2026-08-24T18:27:49.096045+00:00

## What matters in practice
- 21-Hydroxylase deficiency accounts for more than 90% of congenital adrenal hyperplasia and is the most common genetic cause of primary adrenal insufficiency. [4][15][8]
- A positive newborn screen requires pediatric endocrine assessment, confirmatory serum 17-hydroxyprogesterone measurement, and electrolyte plus plasma renin assessment for salt-wasting risk. [22][23]
- In symptomatic patients beyond infancy, obtain an early-morning, pre-8 AM serum 17-hydroxyprogesterone by LC-MS/MS; collect during the early follicular phase in menstruating patients. [22]
- Use cosyntropin stimulation with a complete adrenal steroid profile when baseline 17-hydroxyprogesterone is borderline or biochemical results do not distinguish 21-hydroxylase deficiency from another steroidogenic defect. [22][24]
- Classic disease can cause cortisol and aldosterone deficiency with life-threatening neonatal salt-wasting crisis; hyperkalemia, electrolyte abnormalities, and elevated plasma renin identify mineralocorticoid compromise. [8][23]

## Identify salt-wasting risk before completing etiologic confirmation

Treat newborn evaluation as an adrenal-insufficiency risk assessment, not merely an abnormal screening result.

In a newborn with a screen suggestive of 21-hydroxylase deficiency, arrange urgent pediatric endocrinology assessment and obtain confirmatory serum 17-hydroxyprogesterone, serum electrolytes, and plasma renin activity. Electrolyte disturbance and renin elevation identify infants at risk for salt-wasting crisis. [22][23]

Classic 21-hydroxylase deficiency reduces cortisol synthesis and can reduce aldosterone synthesis; affected infants may develop life-threatening salt-wasting crisis. Female fetuses with classic disease may have virilization from androgen excess, but absence of ambiguous genitalia does not reduce concern for adrenal insufficiency in an infant with an abnormal screen. [8][24]

If clinical concern for classic congenital adrenal hyperplasia is high, cosyntropin testing can be performed at 48 to 72 hours of life, and glucocorticoid treatment is often started while confirmatory results are pending. [24]
- Obtain serum electrolytes and plasma renin activity at initial neonatal assessment to define mineralocorticoid risk. [23]
- Refer infants with positive newborn screening results to pediatric endocrinology; use cosyntropin testing when confirmation is needed. [22]
- Do not wait for a random later 17-hydroxyprogesterone level when salt-wasting disease is clinically plausible; early treatment may be initiated during diagnostic evaluation. [24]

*Clinical branches after an abnormal newborn screen for congenital adrenal hyperplasia. [22][23][24]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Elevated serum 17-hydroxyprogesterone after positive screen | Supports 21-hydroxylase deficiency; confirm biochemical phenotype. [23] | Assess electrolytes and plasma renin activity; involve pediatric endocrinology. [22][23] |
| Electrolyte abnormalities and/or elevated plasma renin activity | Identifies risk for salt-wasting crisis from mineralocorticoid deficiency. [23] | Manage urgently as possible classic salt-wasting disease while endocrine evaluation proceeds. [8][23][24] |
| Only mildly increased 17-hydroxyprogesterone or unclear diagnosis | Screening and baseline testing may not distinguish 21-hydroxylase deficiency from other enzyme defects. [22][23] | Perform cosyntropin stimulation with a complete adrenal steroid profile; consider genotyping. [22][23][24] |

## Use timed 17-hydroxyprogesterone testing and reflex cosyntropin profiling

Sampling conditions determine whether 17-hydroxyprogesterone is an effective diagnostic discriminator.

For symptomatic individuals past infancy, screen with baseline serum 17-hydroxyprogesterone collected before 8 AM and measured by liquid chromatography-tandem mass spectrometry. In menstruating patients, obtain the sample in the early follicular phase to reduce interpretive error from cycle-related steroid variation. [22]

A borderline baseline 17-hydroxyprogesterone should trigger a cosyntropin stimulation test with a complete adrenocortical steroid profile rather than a diagnosis based on one indeterminate value. This approach distinguishes 21-hydroxylase deficiency from other steroidogenic enzyme defects. [22]

A commonly used confirmatory protocol administers 250 micrograms of cosyntropin intravenously and measures serum 17-hydroxyprogesterone plus an adrenal steroid panel at baseline and 60 minutes. The stimulated panel is particularly important beyond the newborn period, when random 17-hydroxyprogesterone may be insufficiently elevated for accurate diagnosis of nonclassic disease. [24]

When stimulated testing remains nondiagnostic, especially in a patient already receiving glucocorticoid therapy, obtain genotyping to clarify the diagnosis. In newborns, genotyping also helps interpret equivocal biochemical results and supports genetic counseling. [22][23]
- Preferred outpatient screening specimen: serum before 8 AM, analyzed by LC-MS/MS. [22]
- Preferred timing in menstruating patients: early follicular phase. [22]
- Indication for cosyntropin testing: borderline baseline 17-hydroxyprogesterone or uncertainty among steroidogenic defects. [22]
- Escalate to genotyping when biochemical testing is equivocal or altered by glucocorticoid exposure. [22][23]

*Testing strategy by clinical setting. [22][23][24]*

| Clinical setting | Initial test | Interpretation and escalation |
| --- | --- | --- |
| Positive newborn screen | Serum 17-hydroxyprogesterone, electrolytes, and plasma renin activity. [23] | Confirm biochemical disease and identify salt-wasting risk; use cosyntropin testing if 17-hydroxyprogesterone elevation is mild or diagnosis is unclear. [22][23] |
| Symptomatic patient past infancy | Pre-8 AM serum 17-hydroxyprogesterone by LC-MS/MS. [22] | If borderline, obtain cosyntropin-stimulated complete adrenocortical profile. [22] |
| Persistent diagnostic uncertainty | Cosyntropin test with baseline and 60-minute adrenal steroid measurements. [24] | Use genotyping when stimulated findings are nondiagnostic, particularly during glucocorticoid therapy. [22] |

## Distinguish 21-hydroxylase deficiency from other steroidogenic disorders

The adrenal steroid pattern, mineralocorticoid phenotype, and sex-steroid precursor profile direct the next diagnostic step.

21-Hydroxylase deficiency is caused by pathogenic variants in CYP21A2 and produces impaired cortisol synthesis, accumulation of precursors including 17-hydroxyprogesterone, increased ACTH drive, and shunting toward adrenal androgen production. The biochemical consequence is central to both newborn screening and targeted confirmatory testing. [9][23][24]

A complete post-cosyntropin steroid profile is required when 17-hydroxyprogesterone is indeterminate because elevated precursor concentrations are not unique to 21-hydroxylase deficiency. The Endocrine Society recommends this strategy specifically to differentiate 21-hydroxylase deficiency from other enzyme defects. [22]

Consider P450 oxidoreductase deficiency when genital or steroidogenic findings suggest congenital adrenal hyperplasia but electrolytes and mineralocorticoid function are normal, cortisol is nearly normal but has a poor ACTH-stimulated response, sex-steroid precursors are low, and progesterone and 17-hydroxyprogesterone have variable ACTH responses. This pattern should redirect testing toward comprehensive steroid profiling and genotype confirmation rather than assumed 21-hydroxylase deficiency. [24]
- High 17-hydroxyprogesterone with androgen excess and cortisol deficiency supports 21-hydroxylase deficiency. [23][24]
- Normal mineralocorticoid function with low sex-steroid precursors favors P450 oxidoreductase deficiency over classic 21-hydroxylase deficiency. [24]
- Use genotype testing as a diagnostic complement when biochemical phenotype is equivocal. [22][23]

*Steroidogenic patterns that alter the diagnostic pathway. [22][23][24]*

| Pattern | Diagnostic implication | Next step |
| --- | --- | --- |
| High 17-hydroxyprogesterone with cortisol deficiency and androgen excess | Compatible with 21-hydroxylase deficiency. [23][24] | Define classic versus nonclassic phenotype and assess mineralocorticoid status with electrolytes and plasma renin activity when relevant. [23] |
| Borderline 17-hydroxyprogesterone | Does not reliably distinguish 21-hydroxylase deficiency from another enzyme defect. [22] | Obtain cosyntropin-stimulated complete adrenocortical profile. [22] |
| Normal electrolytes/mineralocorticoid function, low sex-steroid precursors, poor cortisol response to ACTH | Suggests P450 oxidoreductase deficiency. [24] | Use comprehensive steroid profiling and genotype-directed confirmation. [24] |

## Match therapy and surveillance to cortisol, mineralocorticoid, androgen, and reproductive consequences

Management aims to replace deficient hormones without excess glucocorticoid exposure.

Glucocorticoid replacement is the foundational treatment for 21-hydroxylase deficiency because the disorder is characterized by impaired cortisol synthesis and ACTH-driven adrenal androgen excess. In classic disease, intercurrent illness requires glucocorticoid stress dosing; acute illness poses adrenal-crisis risk particularly in salt-wasting 21-hydroxylase deficiency. [1][8][11]

For patients with classic salt-wasting disease who cannot take oral fludrocortisone, intravenous hydrocortisone at higher doses with sodium chloride can provide temporary mineralocorticoid effect; 20 mg hydrocortisone is described as equivalent to 0.1 mg 9-alpha-fludrocortisone. [11]

Avoid chronic glucocorticoid overtreatment. Adult observational experience describes frequent obesity, adverse health metrics, reduced quality of life, and apparent glucocorticoid overtreatment; chronic therapy in women should use the minimum glucocorticoid amount that maintains an acceptable testosterone concentration, individualized to the patient. [10]

In adult males, evaluate testicular masses or infertility with testicular ultrasonography because testicular adrenal rest tumors may be palpable or detectable only by ultrasound. These ACTH-responsive lesions can regress with adequate glucocorticoid therapy and ACTH suppression, whereas inadequate glucocorticoid control promotes growth. [9]

For women pursuing pregnancy, optimize adrenal replacement before ovulation induction. A follicular-phase progesterone below 0.6 ng/mL (2 nmol/L) is associated with conception; described regimens include multiple daily hydrocortisone and/or prednisolone doses, with a 0.5 to 2 mg bedtime prednisolone dose used alongside daytime hydrocortisone or prednisolone. Ovulation induction may still be needed despite optimized replacement. [10]
- Teach and implement illness-related glucocorticoid stress dosing in classic disease. [11]
- Monitor for consequences of excess glucocorticoid exposure, including weight-related and quality-of-life burden. [10]
- Use testicular ultrasonography when male patients have suspected testicular adrenal rest tumors or infertility. [9]
- In women seeking conception, measure follicular-phase progesterone and intensify adrenal suppression when it remains at or above 0.6 ng/mL. [10]

### Emerging ACTH-directed therapy

Crinecerfont has been evaluated in a phase 3 trial in adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, a population conventionally treated with glucocorticoid replacement. Its role should be considered within specialty-directed management rather than as a substitute for urgent glucocorticoid replacement in cortisol-deficient disease. [1]

*Selected longitudinal management decisions in 21-hydroxylase deficiency. [9][10][11]*

| Clinical problem | Assessment | Management implication |
| --- | --- | --- |
| Intercurrent illness in classic disease | Assess need for glucocorticoid stress dosing and adrenal-crisis prevention. [11] | Provide stress-dose glucocorticoid management; salt-wasting disease has greater adrenal-crisis risk than 11-beta-hydroxylase deficiency. [11] |
| Inability to take oral fludrocortisone | Assess need for temporary mineralocorticoid coverage. [11] | Use higher-dose IV hydrocortisone with sodium chloride; 20 mg hydrocortisone provides mineralocorticoid activity equivalent to 0.1 mg 9-alpha-fludrocortisone. [11] |
| Male infertility or testicular lesion | Testicular ultrasonography for testicular adrenal rest tumor. [9] | Optimize glucocorticoid therapy and ACTH suppression because these lesions may regress. [9] |
| Pregnancy planning | Measure follicular-phase progesterone. [10] | Target progesterone below 0.6 ng/mL (2 nmol/L) with individualized hydrocortisone/prednisolone therapy; consider standard ovulation induction if needed. [10] |

## Use genotyping when it changes diagnosis, counseling, or reproductive planning

Genetic confirmation is most useful when biochemical results are equivocal or family risk requires clarification.

21-Hydroxylase deficiency is an autosomal recessive disorder associated with pathogenic CYP21A2 variants. Use genotyping as a complement to biochemical testing when neonatal or stimulated steroid findings are equivocal and when genotype clarification will inform family counseling. [9][23][24]

Prenatal treatment considerations require specialized expertise because affected female fetuses can undergo virilization from prenatal androgen excess. Establishing the familial molecular diagnosis is therefore clinically relevant before reproductive counseling or any prenatal management discussion. [13][24]
- Offer genetics-focused counseling after diagnostic confirmation because 21-hydroxylase deficiency is autosomal recessive. [9][13]
- Use genotyping to resolve equivocal biochemical testing and support counseling after a positive newborn screen. [22][23]

*Situations in which CYP21A2 genotyping adds clinical value. [22][23]*

| Situation | Why genotype testing helps |
| --- | --- |
| Equivocal newborn biochemical findings | It complements 17-hydroxyprogesterone testing and aids interpretation after newborn screening. [23] |
| Nondiagnostic cosyntropin-stimulated results | It may confirm the diagnosis, particularly when glucocorticoid treatment complicates biochemical interpretation. [22] |
| Family counseling and reproductive planning | It identifies the molecular basis of an autosomal recessive condition for familial risk assessment. [9][13] |

## References
1. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal ... — www.nejm.org — https://www.nejm.org/doi/abs/10.1056/NEJMoa2404656
2. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase ... — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJM199012273232605
3. Adrenomedullary Dysplasia and Hypofunction in Patients ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM200011093431903
4. Congenital Adrenal Hyperplasia — www.nejm.org — https://www.nejm.org/doi/abs/10.1056/NEJMra021561
5. “Nonfunctional” Adrenal Tumors and the Risk for Incident ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M16-0547
6. Future Directions in the Study and Management of ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-136-4-200202190-00012
7. Inherited Forms of Mineralocorticoid Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.HYP.28.6.927
8. Contemporary global management of 21-hydroxylase... : European Journal of Endocrinology — journals.lww.com — https://journals.lww.com/00023063-202602000-00005
9. Hypogonadism - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/hypogonadism
10. Adrenal Crisis - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/adrenal-crisis
11. Hydrocortisone Release - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/hydrocortisone-release
12. 11-Ketotestosterone - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/11-ketotestosterone
13. Prenatal Treatment of Congenital Adrenal Hyperplasia ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1007/s10897-012-9508-8
14. Long‐term health consequences of congenital adrenal ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/cen.14967
15. 21‐Hydroxylase Deficiency - NEWFIELD - 1997 — nyaspubs.onlinelibrary.wiley.com — https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.1997.tb52145.x
16. Glucocorticoid replacement regimens for treating ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012517.pub2/references
17. Adrenal Insufficiency: Still a Cause of Morbidity and Death ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/119/2/e484
18. Term Infant With Ambiguous Genitalia | NeoReviews — neoreviews.aappublications.org — https://neoreviews.aappublications.org/content/14/10/e539
19. Adrenal Insufficiency | Pediatrics In Review — pedsinreview.aappublications.org — https://pedsinreview.aappublications.org/content/36/3/92
20. Primary adrenal insufficiency in adults: When to suspect, how to diagnose and manage | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/91/9/553
21. Evaluation, Treatment, and Prevention of Vitamin D Deficiency — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.1210%2Fjc.2011-0385&link_type=DOI
22. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6456929
23. Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7569755
24. Congenital Adrenal Hyperplasia - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK278953

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.